HistAI Unveils New State-of-the-Art Cell Segmentation and Classification Model: CellViT-Hibou-L

HistAI, an AI-native challenger in computational oncology, is proud to announce the release of its groundbreaking new model, CellViT-Hibou-L. This state-of-the-art cell segmentation and classification model builds on the foundation of CellViT: Vision Transformers for Precise Cell Segmentation and Classification and represents a significant leap forward in the field, outperforming the original model across almost all benchmarks.

CellViT-Hibou-L’s superior performance is powered by our proprietary Large Vision Foundation model, Hibou-L, which has proven to be a robust and generalizable platform for a wide range of computational pathology applications. The success of CellViT-Hibou-L underscores the strength of Hibou-L as a foundational model capable of driving innovation and excellence in medical imaging and analysis.

"We are thrilled to share CellViT-Hibou-L with the research community," said Alex Pchelnikov, CEO of HistAI. "Our model’s ability to surpass the previous state-of-the-art in cell segmentation and classification is a testament to the power and potential of our Hibou-L foundation model. We believe this will be a game-changer in computational pathology, helping researchers achieve faster and more accurate results."

In line with our commitment to fostering open research and innovation, CellViT-Hibou-L is being made available under the Apache 2.0 license with a clause restricting commercial use, inheriting the original license of the CellViT model. This allows researchers and developers to freely utilize and build upon our work while ensuring that the model is used ethically and responsibly.

Additionally, we are excited to announce the release of our Hibou-L foundation model under the Apache 2.0 license without any constraints, enabling free commercial use. This move is designed to accelerate the adoption of Hibou-L in various commercial and research applications, further solidifying its role as a versatile and powerful tool in the computational pathology landscape.

"We envision Hibou-L driving advancements not just in academic research, but across the healthcare industry," added Dmitry Nechaev, Chief AI Scientist. "By making it freely available for commercial use, we aim to empower companies and researchers alike to push the boundaries of what’s possible in medical imaging and beyond."

CellViT-Hibou-L is available on Hugging Face at https://huggingface.co/histai/cellvit-hibou-l

Hibou-L is available on Hugging Face at https://huggingface.co/histai/hibou-L

About HistAI

HistAI is at the forefront of innovation in computational pathology, dedicated to developing cutting-edge tools and technologies that advance medical research and improve patient outcomes. With a focus on open science and collaboration, we aim to provide researchers and clinicians with the resources they need to drive meaningful progress in the fight against disease.